Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Expression data from murine vaginal samples following adjuvant treatment

ABSTRACT: Vaccine research today is focused on using safer, highly purified or recombinant antigens with poor immunogenicity, which has created a need for potent adjuvants. Rational design of effective and safe mucosal adjuvants for human use necessitates a thorough understanding of the mode of action of successful candidate adjuvants. We used microarray to comprehend the molecular signatures of mucosal adjuvants in the mouse vagina. The adjuvants studied, CpG-ODN and α-GalCer have previously been shown to be potent mucosal adjuvants in mice when administrered together with a glycoprotein from HSV-2. Two individual experiments were performed, called ES1 and ES2, each experiment contained 4 groups of mice. All mice were pre-treated with progesteron (DP) before intravaginally recieveing either CpG ODN, alpha-GalCer or their respective buffers, PBS and PBS/Tween. Vaginas were excised at 3 different time-points; 4h, 24h and 48h following adjuvant delivery.

ORGANISM(S): Mus musculus

SUBMITTER: Ali Harandi 

PROVIDER: E-GEOD-27149 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Json Xml
altmetric image

Publications

Unraveling molecular signatures of immunostimulatory adjuvants in the female genital tract through systems biology.

Lindqvist Madelene M   Nookaew Intawat I   Brinkenberg Ingrid I   Samuelson Emma E   Thörn Karolina K   Nielsen Jens J   Harandi Ali M AM  

PloS one 20110607 6

Sexually transmitted infections (STIs) unequivocally represent a major public health concern in both industrialized and developing countries. Previous efforts to develop vaccines for systemic immunization against a large number of STIs in humans have been unsuccessful. There is currently a drive to develop mucosal vaccines and adjuvants for delivery through the genital tract to confer protective immunity against STIs. Identification of molecular signatures that can be used as biomarkers for adju  ...[more]

Similar Datasets

Transcriptomics Expression data from murine vaginal samples following adjuvant treatment
2011-12-30 | GSE27149 | GEO
Transcriptomics Transcription profiling time course of mouse lung after in-vivo intrapulmonary administration of CpG.
2009-11-14 | E-TABM-823 | biostudies-arrayexpress
Transcriptomics Molecular Characterization of In Vivo Adjuvant Activity in Ferrets Vaccinated against Influenza Virus
2011-02-11 | E-GEOD-27248 | biostudies-arrayexpress
Transcriptomics Gene expression profile of IGROV1 cells after in vitro treatment with CpG-ODN
2011-04-01 | GSE23442 | GEO
Transcriptomics CpG Oligodeoxynucleotides treatment of Anopheles mosquitoes
2013-04-02 | GSE26941 | GEO
Transcriptomics Expression data from Middle Ear Mucosal Metaplasia in Mice
2012-11-13 | E-GEOD-40087 | biostudies-arrayexpress
Proteomics TLR9-activated B cells imprint adoptively transferred CD8+ T cells with potent tumor immunity and persistence
2022-02-22 | PXD022909 | Pride
no omics defined Transcription profiling of mouse muscle tissue after in-vivo intramuscularly administration of MF59, CpG, MF59+CpG, alum and PBS
2009-07-03 | E-TABM-506 | biostudies-arrayexpress
Transcriptomics MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I independent mechanism of action
2012-02-22 | E-MTAB-942 | biostudies-arrayexpress
Transcriptomics Exon arrays of ENCODE tier 1, tier 2 and tier 3 cell types
2009-11-19 | E-GEOD-19090 | biostudies-arrayexpress